Adcentrx Therapeutics

Adcentrx Therapeutics is a biotechnology company founded in 2021, with the mission of accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. The company's slogan "Merging Chemistry and Biology to Benefit the Lives of Patients" embodies its approach. By combining the targeting precision of biologics with the disease-fighting power of small molecule payloads, Adcentrx is committed to developing next-generation targeted therapies to improve patient treatment options. The company recently received a substantial $51.00M Series A investment on 24 April 2023, from a strong consortium of investors including Eight Roads Ventures, F-Prime Capital, Partners Investment, Delta Capital, Lighthouse, Quan Capital, Trinity Innovation Fund, and ABio-X. The fact that such reputable investors have shown confidence in Adcentrx's potential indicates the strength of the company's approach and the promise of its innovations. With its headquarters in the United States, Adcentrx Therapeutics is strategically positioned within a leading hub for biotechnology and pharmaceutical innovation, providing access to top talent and resources in the field. As the company continues to progress, it is poised to make significant contributions to the advancement of targeted therapies, potentially reshaping the landscape of treatment options for cancer and other life-threatening diseases.